BPC-157 + TB-500 Research Stack
Research compounds — not for human consumption
Recovery Research Stack — BPC-157 + TB-500
Both compounds supplied together as a single research stack — priced below buying each separately.
Overview
BPC-157, a synthetic pentadecapeptide derived from a sequence in a gastric protein, and TB-500, a synthetic peptide corresponding to the actin-binding region of Thymosin Beta-4, are frequently examined together in tissue-repair research. Each compound has its own independent body of preclinical literature; interest in the pairing arises from their distinct but potentially complementary mechanisms of action in laboratory models.
Compounds in this stack
Areas of Combined Research Interest
Preclinical research on BPC-157 has examined angiogenic signaling, growth-factor pathways such as VEGF, nitric-oxide regulation, and fibroblast behaviour in tendon and ligament models. Research on TB-500 centers on actin sequestration, cell migration, and vascularization. Investigators who study the two compounds together are typically interested in whether these separate mechanisms — one emphasizing growth-factor and vascular signaling, the other cytoskeletal remodeling and cell motility — can be characterized in parallel within a single connective-tissue-repair model. Published data specific to the combination remains limited, and most rigorous work evaluates each compound on its own.
Storage & Handling
Both compounds are typically supplied as lyophilized powder and, in research settings, are stored sealed and protected from light, with reconstituted solutions kept refrigerated. Handle per standard laboratory practice.
References
References are provided for scientific context. Combination-specific data is limited; most published research characterizes each compound individually. Linked sources are independent and not affiliated with iNGEN MD.